Now on ScienceBlogs: HeartlandGate: Anti-Science Institute's Insider Reveals Secrets

ScienceBlogs Book Club: Inside the Outbreaks

Neuron Culture

David Dobbs on science, nature, and culture.

Search

Profile

dobbspic I write articles on science, medicine, nature, culture and other matters for the New York Times Magazine, The Atlantic, Slate, National Geographic, Scientific American Mind, and other publications, and am working on my fourth book, The Orchid and the Dandelion, which expands on my recent December 2009 Atlantic article. In August 2010, I'll be moving to London for a year to work on the book. I'll also serve as a senior fellow at City University London's MA science journalism program.

You're encouraged to check out my third book Reef Madness: Charles Darwin, Alexander Agassiz, and the Meaning of Coral, which traces the strangest but most forgotten controversy in Darwin's career; subscribe to Neuron Culture by email; see more of my work at my main website; or track Twitter feed, my Google Reader shared items, or my Tumblr log, which gets it all.

Twitterature>

Twitter Updates

    Follow me on Twitter

    Worth Noting

    Recent Posts

    Recent Comments

    Categories

    « Hits of the week past | Main | The mojo of open journalism, plus that itchy beta thing »

    The Rise Of Marketing-Based Medicine (via Pharmalot)

    Posted on: January 31, 2010 2:14 PM, by David Dobbs

    The Rise Of Marketing-Based Medicine

    64 Comments

    By Ed Silverman // January 28th, 2010 // 7:57 am

    money13You've heard of evidence-based medicine. Well, a new paper summarizes a panoply of practices employed over the past two decades or so - ghostwriting, suppressing or spinning data, disease mongering and managing side effect perceptions among docs - that the authors call marketing-based medicine. And they rely on internal documents from litigation - such as the much-publicized lawsuits over antipsychotics and antidepressants - to illustrate their point.

    A stunning must-read from Ed Silverman on a must-read paper. The comments following Ed's post are also rich.

    I imagine there will be blowback and some vigorous challenges to the facts and stats in the paper. But the industry emails quoted are themselves devastating, and suggest how successfully the marketing forces within the industry won out over those who wanted to make drugs that clearly worked, rather than aggressively sell drugs that either didn't work that well or worked for some but carried nasty side-effects that were downplayed.

    Pharma, biotech, and medicine itself will be years digging out of the credibility hole this sort of thing put them in.

    Posted via web from David Dobbs's Somatic Marker

    Share on Facebook
    Share on StumbleUpon
    Share on Facebook

    TrackBacks

    TrackBack URL for this entry: http://scienceblogs.com/mt/pings/130720

    Comments

    1

    My favorite side effect from the drug commercials (I forget which drug, unfortunately) is "skeletal pain."
    Ow. My skeleton hurts.
    If you can't develop new treatments for old diseases, just invent new diseases for your old treatments.

    Posted by: feralboy12 | January 31, 2010 2:56 PM

    Post a Comment

    (Email is required for authentication purposes only. On some blogs, comments are moderated for spam, so your comment may not appear immediately.)





    ScienceBlogs

    Search ScienceBlogs:

    Go to:

    Advertisement
    Follow ScienceBlogs on Twitter

    © 2006-2011 ScienceBlogs LLC. ScienceBlogs is a registered trademark of ScienceBlogs LLC. All rights reserved.